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Introduction: Acromegaly is a disease in which uncontrolled release of growth hormone occurs
after closure of epiphyseal plates, causing changes in the body that can lead to sleep disor-
dered breathing (SDB). No definite guidelines regarding the treatment of SDB in acromegaly
are available. In this study, we aimed to investigate the prevalence of SDB in acromegaly
and whether hormonal control alters the necessity of positive airway pressure (PAP) therapy
in acromegaly patients with SDB.
Methods: Forty-two acromegaly patients were included in the study and divided into two
groups according to disease status, i.e., active or well controlled. All patients underwent poly-
somnography. Fourteen patients with active acromegaly were diagnosed with SDB and were
evaluated for PAP therapy with polysomnography both before and 6 months after disease con-
trol was achieved.
Results: Sleep-disorder breathing was diagnosed in 22 of 42 patients, 7 of 20 patients with
controlled-disease and 15 of 20 patients with active diseases. There were significant reduc-
tions in respiratory disturbance index (RDI), apnea index, desaturation index, central apnea
number, and rapid eye movement-phase RDI at the control polysomnography. Initially, PAP
therapy was indicated in 12 of 14 patients and PAP therapy indication held in 11 patients after
acromegaly control was achieved.
Conclusion: Our study revealed that over half of patients with acromegaly had SDB. Further-
more, SDB severity decreases with acromegaly treatment; however, this decrease does notakif University, Department of Pulmonology, Aksaray Mah. Vatan Cad., 34095 Fatih, Istanbul, Turkey.
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1804 M.E. Akkoyunlu et al.change the indication for PAP therapy; therefore, PAP therapy should not be delayed in acro-
megalic SDB patients.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Sleep-disorder breathing (SDB) is a disease characterized by
fragmented sleep and day-time sleepiness. There are many
pathological components in its etiology. Although 27e80%
of acromegaly patients have SDB, the rarity of acromegaly
in the general population (2e4 cases/million) leads to an
underestimated incidence [1e4]. Moreover, the leading
cause of death in acromegaly is cardiovascular complica-
tions, and there is a definite relationship between SDB and
cardiovascular diseases in patients with acromegaly [1].
Growthhormone (GH)and insulin-likegrowth factor-1 (IGF-
I) are essential for the regulation of metabolism and body
composition. Uncontrolled release of growth hormone after
closure of epiphyseal plates leads to asymmetrical growth and
bizarre hormonal changes in the body, particularly facial bone
changes, edema, and hypertrophy of the upper airway mu-
cosa, growth of the pharyngeal and laryngeal cartilages, nasal
polyps, and increased size of the tongue; these can trigger
obstructive sleep apnea syndrome (OSAS) [1e4]. Also, in-
creased growth hormones and changes in the somatostati-
nergic system can lead to central sleep apnea syndrome [4].
The associationbetweenhormoneactivity level (GH/IGF-I)
and SDB is controversial. Some studies have shown convincing
data regarding the relationship between SDB frequency and
disease activity (GH/IGF-I activity) in active acromegaly pa-
tients [5e9]. Some studies indicate an association between
disease activity and central sleep apnea syndromeprevalence
[10], but others reported no such association [11]. In the
literature,OSAS ismarkedlymoreprevalent thancentral sleep
apnea syndrome in acromegaly patients [5,6,12].
Although the relationship between acromegaly and SDB
is well known, the effect of acromegaly control on the
course of SDB is controversial [1,3,5,11]. It is postulated
that if the acromegaly can be controlled, central sleep
apnea syndrome and OSAS, due to hormonal and structural
changes, will regress. However, some studies have shown
that, due to permanent structural changes, SDB can remain
even after complete hormonal treatment of acromegaly
[1,7,13]. The efficacy of hormonal control in the treatment
of SDB due to acromegaly is unclear, and no study has
investigated the necessity of positive airway pressure (PAP)
therapy after hormonal control.
In this study, we aimed to investigate the prevalence of
SDB in active and controlled acromegaly patients and
determine whether hormonal control alters the necessity of
PAP treatment in acromegaly patients with SDB.
Patients and methods
Forty-two acromegaly patients who attended the Bezmia-
lem Vakif University Endocrinology department between
1st January 2010 and 31st December 2012 were included in
the study. Patients were divided into two groups accordingto disease status: active disease (n Z 22) and controlled
disease (n Z 20). The active disease group consisted of
newly diagnosed naive cases (n Z 15) and uncontrolled
patients (n Z 7) who were diagnosed previously but whose
disease was unable to be controlled with ongoing therapy.
Patient selection and study phases are shown in Fig. 1. All
patients underwent full night polysomnography. Fifteen of
the 22 uncontrolled group patients were diagnosed as SDB
and they were evaluated for PAP treatment according to
the “American College of Chest Physicians Sleep Medicine
Board Review: 4th edition” [14]. Of the 22 uncontrolled
group patients, 7 had normal polysomnography results and
were thus considered not to have SDB. They were discarded
from follow-up (Fig. 1). Adults with moderate-to-severe
OSAS must meet one of the following apnea-hypopnea
index (AHI) criteria: A) AHI 15 events per hour, with or
without symptoms; or B) AHI 5 events per hour and 14
events per hour, with documented symptoms of excessive
daytime sleepiness, impaired cognition, mood disorders, or
insomnia, documented hypertension, ischemic heart dis-
ease, or history of stroke. One acromegaly patient with SDB
left the study for personal reasons. Disease activity in the
active disease group was controlled with medical treatment
(cabergalin, lanreotid acetate, pegrisomant, and octreo-
tide), surgery or radiotherapy, or with combinations of
these. Fourteen patients were observed for 6 months after
disease control was achieved without any treatment for
SDB, and had control polysomnography. Median duration for
achieving hormonal control was 8 months.
The procedures were in accordance with the guidelines of
the Helsinki Declaration on human experimentation. Info-
rmed consent was obtained from all subjects. The study
protocol was approved by the Institutional Ethics Committee.
Hormone assays
The diagnosis of acromegaly is made on the typical
appearance of the patient and serum IGF-I or/and without
suppression of GH <1 ug/l to an oral glucose tolerance test
[15]. Blood GH and IGF-I levels were assayed using a
chemiluminescence immunometric assay (Siemens Advia-
Centaur USA). Age-related reference ranges for IGF-I were
as follows: 18e20: 197e956; 20e23: 215e628; 23e25:
169e591; 25e30: 119e476; 30e40: 100e494; 40e50:
101e303; >50: 78e258. The cut-off level for GH was 2 ng/
ml. The criteria for absence of clinical activity were normal
levels of IGF-I, taking into account age and sex and a GH
nadir value less than 1 mg/l [15].
Polysomnography evaluation
A Compumedics E 3142 polysomnography device was used
(Compumedics Inc., Melbourne, Australia) for poly-
somnography, and findings were evaluated based on the
Figure 1 Flow chart of study.
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Medicine in 2007 [16]. The respiratory disturbance index
(RDI) was calculated by dividing the total number of epi-
sodes of apnea, hypopnea, and respiratory-related arousals
by the total sleep time. Apnea was defined as complete
cessation of airflow for 10 s. Hypopnea was defined as a
reduction of more than 50% of three respiratory signals,
airflow signals, or either respiratory or abdominal signals of
respiratory inductance plethysmography, with an associ-
ated decrease of 3% in oxygen saturation or an arousal.
OSAS was defined as an AHI of 5 with associated symptoms
(sleep attacks or excessive daytime sleepiness), unsatisfy-
ing sleep, fatigue or insomnia, or heavy snoring and/or
breathing pauses reported by the subject’s partner), or anAHI 15 regardless of associated symptoms [16]. Patients
were considered to have rapid eye movement (REM) related
SDB if they met the following criteria: age 18 years, AHI
5, non-REM AHI <15, REM AHI to non-REM AHI ratio >2,
and, total time spent in REM of >10 min [16]. The poly-
somnography data were reviewed by two investigators
(MEA, and HKO).Statistics
All statistical analyses were performed using the commer-
cially available SPSS v.16.0 software package (SPSS Inc.,
Chicago, IL, USA). The results are presented as medians and
Table 1 Demographic and anthropometric parameters, co-existing diseases and treatment types.
Controlled
n Z 20
Active
n Z 22
All cases
n Z 42
Male gender 7 (35) 11 (50) 18 (43)
Age, years 41 (33e44) 41 (37e57) 41 (35e41)
Body mass index (kg/m2) 29 (25.2e33.5) 30 (27e32.2) 31 (31e33)
Epworth sleepiness scale 4.5 (2e11) 6 (3e9.2) 5 (2e10)
Neck circumference, cm 37.5 (34.5e42) 39 (35.5e43) 39 (34e43)
Waist circumference, cm 96.5 (91.2e106) 97 (89e106) 97 (90e106)
Growth hormone, ng/ml 0.78 (0.35e1.71) 3.35 (1.6e8.1) 1.57 (1.15e6.18)
IGF-I, ng/ml 229 (170e289) 709 (533e1025) 617 (478e752)
Smoking Current 3 (15) 6 (27) 9 (21)
Former 8 (40) 5 (23) 13 (31)
Never 9 (45) 11 (50) 20 (48)
Diabetes mellitus 2 (10) 6 (27) 8 (19)
Hypertension 5 (25) 6 (27) 11 (26)
Coronary artery disease 0 2 (9) 2 (5)
Treatment Surgery e 5 (23) 7 (17)
Medical e 4 (18) 4 (10)
Medical þ surgery e 12 (54) 22 (52)
Medical þ surgery þ radiotherapy e 1 (4) 9 (21)
Data are presented as numbers (percentages) or medians (25the75th percentile). Abbreviations: ESS; Epworth sleepiness scale, IGF;
insulin-like growth factor.
Table 2 Comparison of sleep disorder parameters be-
tween patients with non-SDB and those with SDB.
Non-SDB
n Z 20
SDB
n Z 22
p
Male gender 4 (20) 14 (64) 0.004
Age, years 36 (38e41) 50 (38e58) 0.001
Duration between
symptom to diagnosis,
years
5 (3e8) 5 (3e7) NS
Treatment duration,
months
6.5 (3e8.7) 25 (6.5e60) 0.002
Growth hormone, ng/ml 1.37
(0.67e3.35)
1.77
(0.99e5.98)
NS
IGF-I, ng/ml 316
(191e533)
617
(244e838)
NS
Epworth sleepiness scale 5 (2e8) 6 (3e11) NS
Body mass index, kg/m2 29 (26e33) 31 (27e35) NS
Neck circumference, cm 36.5 (34e39) 42 (38e44) 0.003
Waist circumference
index, cm
94
(92.25e99)
99 (93e108) 0.038
Data are presented as numbers (percentages) or medians
(25the75th percentile).
Abbreviations: SDB; sleep-disorder breathing, IGF; insulin-like
growth factor.
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The ManneWhitney U test was used to compare the
continuous parameters of SDB and non-SDB patients. The
chi-square test was used to compare non-parametric vari-
ables. The Wilcoxon signed-rank test was used to compare
the first and control polysomnography parameters.
Results
SDB was diagnosed in 22 of 42 patients. In subgroup anal-
ysis, 7 of the 20 patients with controlled disease and 15 of
22 patients with active disease had SDB. There were no
significant differences in demographic and anthropometric
measurements between the groups (Table 1). In the active
acromegaly patients, the median (25the75th percentile)
time to control the disease activity was 8 (5e12) months. In
the controlled disease group, duration of under remission
was significantly higher in the non-SDB group compared to
the SDB group: 21.5 (10e97) vs. 27 (16e84) months,
respectively.
Age, treatment duration, and neck and waist circum-
ferences were significantly higher in the SDB diagnosed
group compared to the non-SDB group (Table 2). Median
(25the75th percentile) IGF-I levels of the SDB-diagnosed
group and the non-SDB group were 316 (191e533) and 649
(246e795), respectively (p > 0.05). According to the poly-
somnography results, severity of SDB was as follows: 7 mild,
4 moderate, and 11 severe patients.
Fourteen active (naive and uncontrolled cases) acro-
megaly patients underwent control polysomnography 6
months after complete control, and significant reductions
in RDI (p Z 0.004), apnea index (p Z 0.014), desaturation
index (pZ 0.023), total central apnea number (pZ 0.037),
and REM RDI (p Z 0.003) were identified (Table 3).Except one patient RDI levels were decreased in all pa-
tients at control polysomnography. Despite the reduction in
RDI, there was no change in the severity of SDB in five pa-
tients. However, three patients became SDB free after
treatment of acromegaly (Fig. 2A). Also, REM RDI and
central apnea index significantly decreased at control pol-
ysomnography (Table 3, Fig. 2B, C).
Table 3 Comparison of before treatment and control polysomnography and anthropometric parameters of active acromegalic
patients with SDB.
n Z 14
Before treatment After treatmenta p
RDI 31.5 (14.4e38.3) 24.6 (12.4e31.4) 0.004
Body mass index 31 (28e36) 31.5 (28e34) NS
Growth hormone, ng/ml 3.57 (1.59e8.15) 1.16 (0.8e1.39) 0.003
IGF-I, ng/ml 718 (605e1023) 137 (124e184) 0.001
Apnea index 17.7 (4.7e27.1) 12.8 (5.5e24.5) 0.014
ESS 6.5 (4e11) 5.5 (3e7.2) NS
Hypopnea 11.2 (6.47e14.3) 9.8 (5.5e12.6) NS
Lowest oxygen saturation 81.5 (75e86) 86 (81.7e89.7) 0.006
Desaturation index 5 (4e6.2) 4 (1.7e6) 0.023
Central apnea 3 (1e12.2) 1 (0e7.2) 0.037
REM-RDI 24.3 (14.1e45.9) 7.8 (1.2e17.2) 0.003
Neck circumference, cm 41 (38e43) 41 (38e43) NS
Waist circumference, cm 100 (93e108) 99 (94e106) NS
Data are presented as medians (25the75th percentile).
Abbreviations: SDB; sleep-disorder breathing, RDI; respiratory disturbance index, IGF; insulin-like growth factor, ESS; Epworth sleepiness
scale, REM-RDI; rapid eye movement phase-respiratory disturbance index, NS; not significant.
a After treatment indicates 6 months after hormonal remission via medical, surgical or radiotherapy or combined.
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polysomnography, and was indicated due to AHI >15 in 10
patients and AHI <15 but with accompanying comorbidities,
such as diabetes mellitus, coronary artery disease and hy-
pertension, in two patients. The indication for PAP therapy
abided at the control polysomnography of 11 patients, even
after acromegaly control was achieved. At the control
polysomnography, one patient showed a reduction in AHI to
13, but PAP remained indicated due to diabetes and coro-
nary artery disease diagnoses.Discussion
Our data revealed that more than half of the patients with
acromegaly had SDB, and that the severity of SDB decreases
with acromegaly treatment but that PAP therapy remains
indicated even after treatment.
Due to the rarity of acromegaly in the general popula-
tion, few studies with small group sizes have investigated
the optimum treatment of SDB in acromegaly. Additionally,
no studies have examined the effect of acromegaly treat-
ment on PAP therapy, which is the essential treatment for
SDB. Given this, should we plan SDB treatment independent
of acromegaly treatment or should we wait until after
acromegaly treatment? There are also no data regarding
the necessity of PAP therapy in conjunction with acro-
megaly treatment, but American college of Chest Physi-
cians Sleep Medicine Board Review advice to respiratory
specialist to remain vigilant for evaluating the patients for
PAP therapy [14].
Davi et al. studied 18 patients with controlled disease
and 18 with uncontrolled disease, and found SDB preva-
lences of 56% and 39%, respectively [3]. However, SDB was
more prevalent in the controlled disease group compared
to the normal population (2e4%) [17,18]. Some studies have
shown that SDB does not completely regress in acromegalypatients if permanent structural changes have occurred
[5,13,19,20]. Our data suggest that the incidences of SDB in
both controlled and uncontrolled patients are higher than
in the normal population.
Obstructive sleep apnea is more common in acromegaly
patients [7e9]. Our results are also similar to the literature.
We found no relation between having SDB and serum IGF-I
levels. The difference between the median serum IGF-I
levels of our SDB and non-SDB patients (649 and 316,
respectively) was not statistically significant, but a study
with a larger group of patients may show otherwise. Among
naive patients, central sleep apnea was found in one with
uncontrolled disease and one with controlled disease.
Acromegaly patients have structural changes in the
oropharyngeal soft tissues that have been shown to facili-
tate development of SDB. Decrease in the size of the uvula
and tongue and regression of SDB after hormonal control
have been reported [1,3,21e23]. Regression of SDB is likely
due to normalization of the soft tissue structures, but
permanent bone changes preclude complete regression of
SDB. In our study, all but one patient had decreased RDI
scores at the control polysomnography. Additionally, there
were significant reductions in the central apnea and desa-
turation indices, which are related to SDB complications.
SDB disappeared in only 2 of 14 cases but PAP treatment
was already not indicated in these patients. Berg et al.
reported that respiratory disturbance index was decreased
from 23 to 18 after 6 months of medical treatment [5]. Also,
Sze et al. showed RDI reduction from 41 to 11 after trans-
sphenoidal surgery [1]. Other studies also reported no
regression or complete regression of SDB after treatment
[21e23]. RDI was decreased from 31 to 24 in our study.
Berg et al. [5] showed a significant positive correlation
between the IGF-I level, tongue size, and BMI, but no cor-
relation between the IGF-I level and RDI. Although we did
not examine the upper airways of our patients, their neck
and waist circumferences were significantly larger than in
Figure 2 A e Comparison of respiratory disturbance index levels of at polysomnography before treatment and control, B e
Comparison of REM-Respiratory disturbance index levels of at polysomnography before treatment and control, C e Comparison of
central apnea index levels of at polysomnography before treatment and control.
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reduced despite no change in BMI and neck circumference
in our study. These findings support that hormonal with-
drawal reduces SDB severity without altering the BMI and
neck circumference. However, in the study by Ip et al. [12],
radiological cephalometric analysis showed reduced size of
soft tissues, consistent with previous reports.
The aim of our study was to determine whether or not
hormonal control therapy reduces the need for PAP ther-
apy. Some previous studies as well as the American College
of Chest Physicians Sleep Medicine Board Review: 4th edi-
tion [14] reported improvement in SDB with medical
treatment. For this reason, we delayed initiating PAP
therapy until after medical hormonal control therapy.
In our study, treatment of acromegaly improved the
severity of SDB but did not reduce the need for PAP therapy.
Thus, treatment of acromegaly has a limited effect on the
improvement of SDB.
Six months of acromegaly remission can be considered a
short time interval to observe possible changes in SDB.
However, Ip et al. [12] and Berg et al. [5] showed that a 6-
month remission of acromegaly is sufficient to observe
predicted upper airway changes and improvement in sleep
parameters. In our study, patients were followed for 14
months (8 months for treatment, 6 months for acromegalyremission) without any treatment for PAP and at the end of
the follow-up the need for PAP treatment was not reduced.
It is obvious that large numbers of patients are needed to
demonstrate alterations in the requirement for PAP therapy.
However, acromegaly is a rare disease and studies of this
condition have small numbers of patients or are retrospec-
tive in design. Although we had relatively small group size,
cohort design and evaluating PAP indication before and after
acromegaly treatment are main strengths of our study.
Male gender and age are reported as risk factors for SDB
in acromegaly patients [24e26] which was consistent with
our results. In literature, disease duration was reported to
be associated with SDB frequency [1] but in our study
estimated disease duration was similar in SDB and non-SDB
group. However, the treatment duration was significantly
longer in SDB patients. This discordance could be associ-
ated with the fact that the disease period is based on the
patients’ estimation and cannot be validated. The associ-
ation between the treatment period and presence of SDB
was considered to be more accurate. In the controlled
group also, duration under remission is longer in the SDB
group compared to the non-SDB group.
In conclusion, acromegaly patients were found to have a
higher incidence of SDB than the general population.
Although acromegaly treatment alone can improve the
Sleep disordered breathing in acromegalic patients 1809severity of SDB, this is a limited effect and the requirement
for PAP was not altered. Our findings suggest that although
hormonal therapy can improve SDB, PAP treatment should
be initiated concomitantly, if indicated.
Conflict of interest statement
We hereby declare that we have no conflict of interest
related to the manuscript “Does hormonal control obviate
positive airway pressure therapy in acromegaly with sleep-
disordered breathing?”.
References
[1] Sze L, Schmid C, Block KE, Bernays R, Brandle M. Effect of
transsphenoidal surgery on sleep apnoea in acromegaly. Eur J
Endocrinol 2007;156:321e9.
[2] Mestron A, Webb SM, Astorga R, Benitto P, Catala M,
Gaztambide S, et al. Epidemiology, clinical characteristics,
outcome, morbidity and mortality in acromegaly based on the
Spanish acromegaly registry ( RegistroEspanol de Acromegaly,
REA). Eur J Endocrinol 2004;151:439e46.
[3] Davi VM, CarbonareDL,GiustinaA, FerrariM, FrigoA, Cascio VL,
Francia G. Sleep apnoea syndrome is highly prevalent in acro-
megaly and only partially reversible after biochemical control
of the disease. Eur J Endocrinol 2008;159:533e40.
[4] Fatti LM, Scacchi M, Pincelli AI, Lavezzi E, Cavagnini F. Prev-
alence and pathogenesis of sleep apnea and lung disease in
acromegaly. Pituitary 2002;4:259e62.
[5] Berg C, Wessendorf TE, Mortsch F, Forsting M, Teschler H,
Weischer T, Mann K, Saller B, Herrmann BL. Influence of dis-
ease control with pegvisomant on sleep apnoea and tongue
volume in patients with active acromegaly. Eur J Endocrinol
2009;161:829e35.
[6] Dostalova S, Sonka K, Smahel Z, Weiss V, Marek J, Horinek D.
Craniofacial abnormalities and their relevance for sleep
apnoea syndromea etiopathogenesis in acromegaly. Eur J
Endocrinol 2001;144:491e7.
[7] Weiss V, Sonka K, Pretl M, Dostalova S, Klozar J, Kambousek P,
Marek J, Haas T. Prevalence of the sleep apnea syndrome in
acromegaly population. J Endocrinol Invest 2000;23:515e9.
[8] Rosenow F, Reuter S, Deuss U, Szelies B, Hilgers RD,
Winkelmann W, Heiss WD. Sleep apnoea in treated acro-
megaly: relative frequency and predisposing factors. Clin
Endocrinol 1996;45:563e9.
[9] Watson NF, Vitiello MV. Management of obstructive sleep
apnea in acromegaly. Sleep Med 2007;8:539e40.
[10] Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly.
Ann Intern Med 1991;115:527e32.
[11] Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a so-
matostatin analog, on sleep apnoea in patients with acro-
megaly. Ann Intern Med 1994;121:478e83.[12] Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on
sleep apnoea in acromegaly: correlation with computerized
tomographic cephalometry and hormonal activity. Clin Endo-
crinol 2001;55:477e83.
[13] Attal P, Chanson P. Endocrine aspects of obstructive sleep
apnea. J Clin Endocrinol Metab 2010;95:483e95.
[14] Freedman NS. Positive airway pressure therapy for obstructive
sleep apnea syndrome: the bordsand beyond. ACCP sleep
medicine board reivew. 4th ed. Published by American College
of Chest Physician Nortbrook USA; 2009. p. 293e312.
[15] Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin
North Am 2008;37:101e22 [viii].
[16] Iber C, Ancoli-Israel S, Chesson AL, Quan SF. The AASM manual
for the scoring of sleep and associated events: rules, termi-
nology, and technical specifications. 1st ed. Westchester,
Illionis: American Academy of Sleep Medicine; 2007.
[17] Ko¨ktu¨rk O. Epidemiology of sleep apnea syndrome. Tuberk
Toraks 1998;46:193e201.
[18] Akkoyunlu ME, Altin R, Kart L, Atalay F, O¨rnek T, Bayram M,
Tor M. Investigation of obstructive sleep apnoea syndrome
prevalence among long-distance drivers from Zonguldak,
Turkey. Multidiscip Respir Med 2013;8:10.
[19] Pelttari L, Polo O, Rauhala E, Vuoriluoto J, Aitasalo K,
Hyyppa¨ MT, Kronholm E, Irjala K, Viikari J. Nocturnal
breathing abnormalities in acromegaly after adenomectomy.
Clin Endocrinol 1995;43:175e82.
[20] Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G,
Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A. Medical
treatment of acromegaly: comorbidities and their reversibility
by somatostatin analogs. Neuroendocrinology 2006;83:
249e57.
[21] Hochban W, Ehlenz K, Conradt R, Brandenburg U. Obstructive
sleep apnoea in acromegaly: the role of craniofacial changes.
Eur Respir J 1999;4:196e202.
[22] Herrmann BL, Wessendorf TE, Ajaj W, Kahlke S, Teschler H,
Mann K. Effects of octreotide on sleep apnoea and tongue
volume (magnetic resonance imaging) in patients with acro-
megaly. Eur J Endocrinol 2004;151:309e15.
[23] Isono S, Saeki N, Tanaka A, Nishino T. Collapsibility of passive
pharynx in patients with acromegaly. Am J Respir Crit Care
Med 1999;160:64e8.
[24] Pekkarinen T, Partinen M, Pelkonen R, Livanainen M. Sleep
apnoea and daytime sleepiness in acromegaly: relationship
to endocrinological factors. Clin Endocrinol 1987;27:
649e54.
[25] Van Haute FR, Taboada GF, Correa LL, Lima GA, Fontes R,
Riello AP, Dominaci M, Gadelha MR. Prevalence of sleep
apnea and metabolic abnormalities in patients with acro-
megaly and analysis of cephalometric parameters by mag-
netic resonance imaging. Eur J Endocrinol 2008;158:
459e65.
[26] Kashine S, Kishida K, Funahashi T, Shimomura L. Characteris-
tics of sleep-disordered breathing in Japanese patients with
acromegaly. Endocr J 2012;59:31e8.
